



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Linerixibat

Cat. No.:	HY-16643
CAS No.:	1345982-69-5
Molecular Formula:	C ₂₈ H ₃₈ N ₂ O ₇ S
Molecular Weight:	546.68
Target:	Apical Sodium-Dependent Bile Acid Transporter
Pathway:	Membrane Transporter/Ion Channel
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (91.46 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		1.8292 mL	9.1461 mL	18.2922 mL
		5 mM		0.3658 mL	1.8292 mL	3.6584 mL
		10 mM		0.1829 mL	0.9146 mL	1.8292 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (4.57 mM); Suspended solution; Need ultrasonic					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (4.57 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.57 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC ₅₀ of 42 nM human ASBT. Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment ^{[1][2][3]} .
IC ₅₀ & Target	IC ₅₀ : 42 nM (Apical sodium-dependent bile acid transporter (ASBT)) ^[1]
In Vitro	The zwitterionic, nonhygroscopic, crystalline salt form of Linerixibat (Compound 56) shows good aqueous solubility at pH

7.4 (>7 mg/mL), excellent thermal stability, and did not generate reactive or humanspecific metabolite, characteristics^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Linerixibat (GSK2330672; 0.05-10 mg/kg; oral gavage; twice daily; for 14 days; male ZDF rat) treatment lowers glucose in an animal model of type 2 diabetes^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Zucker Diabetic Fatty (ZDF) rat ^[1]
Dosage:	0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg
Administration:	Oral gavage; twice daily; for 14 days
Result:	Led to a 1.30-1.64% reduction in hemoglobin A1c (HbA1c), a greater than 50% reduction in nonfasted plasma glucose to below 200 mg/dL, and statistically significant higher plasma insulin.

CUSTOMER VALIDATION

- Nat Commun. 2020 Jul 17;11(1):3612.
- Sci Adv. 2021 Feb 3;7(6):eaaz9857.
- Cell Mol Gastroenterol Hepatol. 2021 May 6;S2352-345X(21)00084-9.
- J Lipid Res. 2023 Feb 3.
- Food Funct. 2021 Aug 10.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Wu Y, et al. Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes. J Med Chem. 2013 Jun 27;56(12):5094-114.

[2]. Linerixibat (GSK2330672) granted Orphan Status. September 24, 2019.

[3]. Wang Y, et al. HNF4α Regulates CSAD to Couple Hepatic Taurine Production to Bile Acid Synthesis in Mice. Gene Expr. 2018 Aug 22;18(3):187-196.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA